Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 8/20 | 0.41 |
| ▸ | EDNRA | P25101 | 8/20 | 0.41 |
| ▸ | CCR4 | P51679 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4773314 | 0.87 | EDNRA (0.42) | EDNRBEDNRA | |
| SCHEMBL27541757 | 0.84 | ADAM17 (0.40) | EDNRBEDNRAADAM17 | |
| SCHEMBL3171131 | 0.81 | ADAM17 (0.46) | ADAM17 | |
| SCHEMBL3189490 | 0.80 | AGTR1 (0.36) | EDNRBEDNRAADAM17 | |
| SCHEMBL13531534 | 0.79 | EDNRB (0.42) | EDNRBEDNRACCR4 | |
| SCHEMBL4771492 | 0.78 | AGTR1 (0.51) | EDNRBEDNRA | |
| SCHEMBL4793147 | 0.77 | EDNRA (0.44) | EDNRBEDNRA | |
| SCHEMBL27542919 | 0.76 | AGTR1 (0.46) | EDNRBEDNRA | |
| SCHEMBL27541661 | 0.75 | AGTR1 (0.39) | EDNRBEDNRA | |
| SCHEMBL4770943 | 0.74 | EDNRA (0.61) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | claimed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| EP-1996588-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | Torrent Pharmaceuticals Ltd (IN) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | EDNRB 2/4885EDNRA 1/4885CCR4 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.